Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

Rhea-AI Summary

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has scheduled a conference call and webcast for February 24, 2025, at 8 am E.T. to discuss new data from duvakitug (anti-TL1A) Phase 2b positive results. The presentation will be made at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO).

The discussion will feature Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer, along with external IBD key opinion leaders. Participants must pre-register to obtain call-in details. A webcast replay will be available within 24 hours on Teva's website.

Positive

• Positive Phase 2b results for duvakitug (anti-TL1A) to be presented

Negative

• None.

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on Monday, February 24, 2025. During the conference call, Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer, and external IBD key opinion leaders (KOLs) will discuss new data presented for duvakitug (anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organization (ECCO).

In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.

A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.

About the Teva and Sanofi Collaboration

Teva and Sanofi are collaborating to co-develop and co-commercialize Teva’s duvakitug for the treatment of UC and CD. Each company will equally share the development costs globally, and the net profits and losses in major markets, with other markets subject to a royalty arrangement. Sanofi will lead the Phase 3 clinical development program. Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 57 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop duvakitug for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD), including to proceed to Phase 3 study and obtain required regulatory approvals; our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our substantial indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquires
TevaIR@Tevapharm.com

FAQ

What are the Phase 2b results for Teva's duvakitug (TEVA)?

The Phase 2b results for duvakitug are described as positive and will be presented at the ECCO congress on February 24, 2025, with detailed data to be discussed during a conference call with Teva's Chief Medical Officer and IBD experts.

When will Teva present the new duvakitug data at ECCO 2025?

Teva will present new data for duvakitug during a conference call on February 24, 2025, at 8 am E.T., discussing results presented at the 20th Annual Congress of ECCO.

How can investors access TEVA's duvakitug Phase 2b results conference call?

Investors must pre-register to obtain local or toll-free phone numbers and personal pins. A live webcast will be available on Teva's website at ir.tevapharm.com, with a replay available within 24 hours.

Who will present TEVA's duvakitug Phase 2b results at ECCO 2025?

Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer, along with external IBD key opinion leaders, will present the results.